Quinoline derivative against non-small cell lung cancer
The present application provides a quinoline derivative against non-small cell lung cancer. 1-[[[4-(4-fluoro-2-methyl)-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of non-small cell lung cancer, and relative to placebo, can significantly improve non-small cell lung cancer patients without progression of survival. 1-[[[4-(4-fluoro-2-methyl-1H-indol-5-yl)oxy-6-methoxyquinolin-7-yl]oxy]methyl]cyclopropylamine or a pharmaceutically acceptable salt thereof provided by the present application can be used for the treatment of lung adenocarcinoma, and relative to placebo, can significantly improve lung adenocarcinoma patients without progression of survival.
1. A method of treating advanced and/or metastatic non-small cell lung cancer, the method comprising:
orally administering to a human patient in need of treatment who has received a second-line or a higher-line therapy a therapeutically effective amount of compound I having the following structural formula or a pharmaceutically acceptable salt thereof,
wherein Compound I or the pharmaceutically acceptable salt thereof is administered at intervals and the ratio of the number of days in the dosing period to the withdrawal period is 2:0.5 to 2.
2. The method according to claim 1 , wherein the non-small cell lung cancer is EGFR mutant-negative non-small cell lung cancer.
3. The method according to claim 1 , wherein the non-small cell lung cancer is lung adenocarcinoma.
4. The method according to claim 1 , wherein the non-small cell lung cancer is EGFR mutant-negative lung adenocarcinoma.
5. The method according to claim 1 , wherein the said compound I or the pharmaceutically acceptable salt thereof is a hydrochloride of compound I.
6. The method according to claim 1 , wherein compound I or the pharmaceutically acceptable salt thereof is administered for 2 weeks and then suspended for 1 week.
7. The method according to claim 6 , wherein the daily dose of Compound I or the pharmaceutically acceptable salt is from 3 mg to 30 mg.
8. The method according to claim 1 , wherein compound I or the pharmaceutically acceptable salt thereof is administered once per day with an oral solid preparation.
9. The method according to claim 1 , wherein a dose of 8 mg, 10 mg, or 12 mg of compound I or the pharmaceutically acceptable salt thereof is administered once per day for 2 weeks and then suspended for 1 week.
10. A method of treating advanced and/or metastatic non-small cell lung cancer, the method comprising:
orally administering to a human patient having non-small cell lung cancer who has received a second-line or a higher-line therapy a pharmaceutical composition comprising a therapeutically effective amount of a compound having the structural formula of Compound I and at least one pharmaceutically acceptable carrier,
wherein the pharmaceutical composition is administered at intervals, the ratio of the number of days in the dosing period to the withdrawal period is 2:0.5 to 2.
11. The method according to claim 10 , wherein non-small cell lung cancer is EGFR mutation negative non-small cell lung cancer.
12. The method according to claim 10 , wherein the pharmaceutical composition is a tablet, a capsule, a powder, a granule, or a dropping pill.
13. The method according to claim 1 , wherein compound I or the pharmaceutically acceptable salt thereof comprises a monohydrochloride salt of compound I.
14. The method according to claim 1 , wherein compound I or the pharmaceutically acceptable salt thereof comprises a dihydrochloride salt of compound I.
15. The method according to claim 10 , wherein the pharmaceutical composition is administered for 2 weeks and then suspended for 1 week.
16. The method according to claim 10 , wherein the pharmaceutical composition is administered for 2 weeks once per day and then suspended for 1 week.